- Business Wire•2 days agoData from Omeros’ OMS721 Phase 2 Clinical Trial in Patients with Stem Cell Transplant-Associated TMA to be Presented at International Transplant Conference
Omeros Corporation today announced that an abstract highlighting positive results from the ongoing OMS721 Phase 2 clinical trial in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy has been accepted for presentation at the 2017 Tandem Meeting of the American Society of Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant ...
- Business Wire•3 days agoOmeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment
Omeros Corporation today announced that, following physician request, it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell transplant-associated thrombotic microangiopathy who is currently receiving the drug under the company’s compassionate use program.
- Motley Fool•3 days ago
Ambitious goals appear within reach after a positive earnings report.
OMER : Summary for Omeros Corporation - Yahoo Finance
Omeros Corporation (OMER)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||9.83 - 10.44|
|52 Week Range||7.20 - 16.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.88|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|